A modest experiment deserves a decision of the right size
Our reminder trial produced forty-two renewals against thirty-four in the comparison group. We kept the positive signal, its uncertainty and its costs together before deciding what to do next.
Forty-two renewals in one group and thirty-four in the other gave our reminder trial an encouraging direction. Four hundred eligible adult business accounts had been randomly assigned: two hundred received the reminder offer and two hundred followed the usual process. Both groups had the same eight-week outcome window. The observed rates were 21% and 17%, a four-percentage-point difference. The commercial team wanted to expand the programme. I wanted another planned evaluation before full rollout. Neither position was unreasonable, and the decision required more than repeating the difference more confidently.
The trial cost ₹18 lakh. That expense belongs in the account because evidence is not free, and a cautious next step can also consume resources. I do not describe the trial as a profit result. Completed renewals are not the same as net contribution after the intervention's costs and any other consequences. Nor does the positive difference settle the effect across customers beyond the eligible group. The task was to decide what this evidence justified next, with both its value and its limits intact.
Define the choice before the result arrives
A commercial experiment is easier to interpret when the possible decisions are considered in advance. What result would support expansion? What would call for another test, a narrower use or an end to the programme? Those questions do not require pretending that every outcome can be anticipated precisely. They establish the relationship between the evidence being collected and the commitment management may make. Without that connection, a positive number can become a reason for whatever action the sponsor already preferred.
Our trial used random assignment, which strengthened the basis for comparing the offered and usual-process groups. That does not mean every remaining question vanished. We still needed to understand uncertainty around the observed difference, how the programme was executed and whether one account's treatment could influence another. The original allocation and the agreed outcome window needed to remain visible. A later selection of responsive accounts would answer a different question from the one the trial had been designed to examine.
The commercial argument for moving quickly had substance. Reminders were a practical programme, and further delay might postpone useful customer contact. A data leader should not treat every request for action as impatience with evidence. The sponsor was responsible for a business opportunity, while my team was responsible for explaining what the trial could support. We needed a shared account of the next commitment's cost and reversibility, not a contest in which analytical caution automatically won the moral argument.
I recommended another prespecified trial because the observed signal was modest relative to the broader claim being proposed. Prespecification meant deciding the evaluation approach before observing the next result, not continuing the exercise until the numbers looked favourable. The choice retained the promising direction while asking for evidence better matched to a full rollout. Customer permissions, programme terms and the actual commercial action remained with their qualified owners. The data team did not acquire authority over those matters by designing the comparison.
Keep the comparison and its limits together
The four-point difference should be reported as an observed result in this trial. It is possible to say that clearly without either declaring a universal effect or dismissing the work. Random assignment gives the comparison a stronger foundation than a simple before-and-after account in which many conditions may have changed. A small observed difference still requires careful assessment of how much uncertainty remains and whether the possible benefit matters after costs. Both statements can be true at once.
I avoid translating the result into a confident total of additional renewals across the whole customer base. Such a projection would require assumptions about other accounts, the delivery of the programme at scale and the stability of the effect. It might be useful as a clearly labelled scenario, but it would not become an observed outcome. A board paper should not let the visual proximity of a trial result and a rollout forecast make them appear to have the same evidential status.
There is also a temptation to search the trial afterwards for the subgroup with the largest difference. That can generate a question worth testing, but it should not be presented as though the subgroup had been the original basis of the experiment. In our account, we retained the full assigned groups and the stated window. We did not replace the modest overall signal with a retrospectively chosen success story. A useful exploratory finding needs its own honest description and, where appropriate, a later evaluation.
The economic question deserves equal care. A renewal may bring revenue while also requiring equipment, service work and continued customer support. The reminder programme has its own expense. Finance and operating colleagues need to assess the relevant consequences before a positive response difference becomes a claim of commercial value. The experiment supplies evidence about behaviour within its scope; it does not complete the enterprise's investment appraisal. Keeping those responsibilities connected prevents the data result from becoming a substitute for the rest of the decision.
Make the next commitment answer the remaining question
The appropriate next step depends on what management still needs to know. Repeating a trial without changing its decision value can waste time. Expanding it indiscriminately can expose more customers and consume more resources without resolving the important uncertainty. We wanted a planned evaluation tied to the rollout question, with clear responsibility for execution and interpretation. The choice should explain how the next evidence could change the decision rather than merely make the existing chart more impressive.
I would establish that decision framework earlier next time. Before launch, I would ask the sponsor and the relevant professional owners to describe plausible actions under several kinds of result, including a modest positive difference. That discussion can reveal whether the organisation is prepared to learn or only waiting for confirmation. It can also show where a smaller reversible action might be justified sooner, so analytical discipline does not become a habit of postponement detached from commercial reality.
The case is not an argument that every programme needs certainty before it begins. Business decisions rarely have that luxury. It is an argument for making the size of the commitment answerable to the strength and relevance of the evidence. A trial can be useful even when it does not settle a rollout. Its value may be to narrow the question, expose a cost or show that a larger claim deserves a more suitable test.
For a board, the practical contribution is to ask how management moved from the observed result to the proposed action. Directors need not supervise every analytical choice to require a clear account of the comparison, uncertainty, economics and remaining question. The positive signal should remain in view, as should the reasons it did not yet justify the largest commitment. That is how an experiment becomes part of judgement rather than a number recruited to endorse a decision already made.